MedTrace Logo

Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

NCT05881837 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2025-04-30

No results posted yet for this study

Summary

To evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

DRUG

HRS9531 injection

HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks

DRUG

HRS9531 injection

HRS9531 injection: dose level 2

DRUG

HRS9531 injection

HRS9531 injection: dose level 3

DRUG

HRS9531 injection

HRS9531 injection: dose level 4

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks、HRS9531 injection level 2 for 20 weeks

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks、HRS9531 injection level 2 for 20 weeks

DRUG

HRS9531 injection Placebo

Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-13
Primary Completion
2024-10-13
Completion
2024-10-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05881837 on ClinicalTrials.gov